/Companies

Scioto Biosciences

Indianopolis, US · Founded 2017 · 7 known investors

Find your way into Scioto Biosciences

Each arrow is one introduction. Sign up to fill in the first one.

113 people can intro you to Jim

Ask Jamie Stiff to introduce you to Jim Schulz

You →Jamie · together at Naurex, Inc. →Jim

27 people can intro you to Mark

Ask Jamie Chen to introduce you to Mark Heiman

You →Jamie · together at Microbiome Therapeutics →Mark

Sign up to find every way you can get introduced to Scioto Biosciences

  • Your email: who you already know at Scioto Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Scioto Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Scioto Biosciences is a life sciences company with corporate offices and research facilities in Fishers, Indiana. This page describes its office locations and employee benefits rather than detailing its products.

Founders & leadership

Scioto Biosciences was founded in 2017 by Joe Trebley and Jim Schulz.

JTJoe Trebley
Joe TrebleyFounder & Chief Executive Officer
JSJim Schulz
Jim SchulzFounder & Chief Financial OfficerHe has prior experience in the biotechnology industry and expertise in business planning, medical devices, and mergers & acquisitions.
MHMark Heiman
Mark HeimanCSODr. Heiman earned a Ph.D. in Physiology from LSU School of Medicine and completed postdoctoral training in neuroendocrinology at Indiana University School of Medicine. He co-invented the drug Lanreotide while at Tulane University School of Medicine, subsequently led metabolic physiology research at Eli Lilly for over two decades including discoveries in leptin and ghrelin regulation, and later served as Chief Scientific Officer of MicroBiome Therapeutics before joining Scioto Biosciences.
KM
Kevin MeyerChief Operating Officer

Investors · 7

Also in the syndicate · 1

Genome & Companylead

Funding

SEC filings, press & company announcements

$1.8M disclosed across 1 of 2 rounds · 2018–2020

  • Undisclosed amountSeries BAug 2020

    Genome & Company (lead)

    Source ↗
▶$1.8MraisedMay 2018 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark HeimanExecutive Officer
  • Joseph TrebleyExecutive Officer, Director
  • James SchulzExecutive Officer, Director
  • Kevin MeyerExecutive Officer
Offering amount
$4M
Amount sold
$1.8M
First sale
Apr 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$2.3M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Scioto Biosciences do?
Scioto Biosciences is a life sciences company with corporate offices and research facilities in Fishers, Indiana. This page describes its office locations and employee benefits rather than detailing its products.
Who founded Scioto Biosciences?
Scioto Biosciences was founded by Joe Trebley, Jim Schulz in 2017.
Who are Scioto Biosciences's investors?
Scioto Biosciences's investors include Elevate Ventures, IU Ventures, Michigan Capital Network, Pathway Bioventures, BioCrossroads, Rev1 Ventures.
How much funding has Scioto Biosciences raised?
Scioto Biosciences has disclosed $1.8M raised across 1 of its 2 known rounds.
Where is Scioto Biosciences headquartered?
Scioto Biosciences is headquartered in Indianopolis, US.